60 patents
Page 2 of 3
Utility
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
23 Feb 23
The present disclosure relates to mTOR inhibitors.
Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
Filed: 29 Apr 22
Utility
Ras inhibitors
31 Jan 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. Koltun, James Cregg, Adrian L. Gill, Andreas Buckl, Yang Liu
Filed: 4 Nov 20
Utility
Ras Inhibitors
15 Dec 22
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Andreas BUCKL, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN, Christopher SEMKO
Filed: 5 May 22
Utility
C26-LINKED Rapamycin Analogs As Mtor Inhibitors
27 Oct 22
The present disclosure relates to mTOR inhibitors.
Christopher Michael SEMKO, Gang WANG, G. Leslie BURNETT, James Bradley AGGEN, Gert KISS, James Joseph CREGG, Micah James Evans GLIEDT, Jennifer PITZEN, Julie Chu-Li LEE, Walter WON, Arun P. THOTTUMKARA, Adrian Liam GILL
Filed: 30 Oct 20
Utility
Solid Forms of {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, a SHP2 Inhibitor
22 Sep 22
The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
Shaoling LI, Steven G. BALLMER
Filed: 29 Nov 21
Utility
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
21 Jun 22
The present disclosure relates to mTOR inhibitors.
Jennifer Pitzen, G. Leslie Burnett, James Bradley Aggen
Filed: 28 Oct 20
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
12 May 22
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein).
Gregory Lawrence VERDINE, M. James NICHOLS, Dylan Talbot STILES, Neville John ANTHONY, Brian Roger BOWMAN, Mathew Edward SOWA, Sharon Ann TOWNSON
Filed: 10 Jun 21
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
12 May 22
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250.
Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
Filed: 11 Jun 21
Utility
Bicyclic Heteroaryl Compounds and Uses Thereof
5 May 22
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Andreas BUCKL, James Joseph CREGG, Naing AAY, Arlyn A. TAMBO-ONG, Elena S. KOLTUN, Adrian Liam GILL, Severin THOMPSON, Micah J Gliedt
Filed: 2 Mar 20
Utility
Identifying New Therapeutic Agents
17 Mar 22
Disclosed herein are methods for identifying novel drug candidates.
Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
Filed: 21 Dec 20
Utility
SHP2 Inhibitor Compositions for Use In Treating Cancer
3 Feb 22
The present disclosure provides methods of treating diseases or disorders using allosteric inhibitors of SHP2 and to methods and diagnostic tests for identifying subjects likely to respond to such allosteric inhibitors of SHP2.
Robert J. NICHOLS, Trever G. BIVONA, Dana NEEL
Filed: 6 Apr 21
Utility
Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor
11 Jan 22
The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
Shaoling Li, Steven G. Ballmer
Filed: 26 Feb 21
Utility
Methods and Reagents for Analyzing Protein-protein Interfaces
30 Dec 21
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein.
Gregory L. VERDINE, M. James NICHOLS, Sharon A. TOWNSON, Uddhav Kumar SHIGDEL, Seung-Joo LEE, Dylan T. STILES, Neville J. ANTHONY
Filed: 28 Jan 21
Utility
Bicyclic heteroaryl compounds and uses thereof
9 Nov 21
Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
Filed: 23 Dec 20
Utility
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
4 Nov 21
The present disclosure relates to mTOR inhibitors.
Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
Filed: 28 Oct 20
Utility
Methods and Reagents for Analyzing Protein-protein Interfaces
16 Sep 21
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein.
Mark Joseph MULVIHILL, Meizhong JIN, Nicholas PERL
Filed: 4 Apr 18
Utility
Solid Forms of {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, an SHP2 Inhibitor
19 Aug 21
The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
Shaoling LI, Steven G. BALLMER
Filed: 26 Feb 21
Utility
Compounds that participate in cooperative binding and uses thereof
13 Jul 21
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250.
Gregory Lawrence Verdine, Brian Roger Bowman, Mathew Edward Sowa, Joshua Alan Van Dyke Blodgett, Keith Earl Robison, Dylan Talbot Stiles, Jay Paul Morgenstern, Sharon Ann Townson, Uddhav Kumar Shigdel
Filed: 2 Dec 19
Utility
SHP2 Inhibitor Compositions and Methods for Treating Cancer
27 May 21
The present disclosure provides methods of treating diseases or disorders related to mutations in the SHP2 gene using allosteric inhibitors of SHP2 and methods and diagnostic tests for identifying subjects susceptible or resistant to allosteric inhibitors of SHP2.
David E. WILDES, Carlos STAHLHUT-ESPINOSA, Robert J. NICHOLS
Filed: 6 Oct 20
Utility
Bicyclic Heteroaryl Compounds and Uses Thereof
13 May 21
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
Filed: 5 Nov 20